Skip to main content
Tralokinumab improves clinical responses at week 16 in moderate-to-severe AD despite IGA 0/1 nonachievement
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Tralokinumab improves clinical responses at week 16 in moderate-to-severe AD despite IGA 0/1 nonachievement
User login
Username
Password
Reset your password
Concept
Lead
score
Dermatitis
1
1
Child
0
0.83
Inflammatory Bowel Disease
0
1
Atopic Dermatitis
0
1
Ulcerative Colitis
0
0.65
Crohn Disease
0
0.65
Colitis
0
0.1
Specialty
Lead
score
Dermatology
1
1
Family Medicine/Primary Care
0
1
Gastroenterology
0
0.97
Pediatrics
0
0.93
Nursing
0
0.65
Edit Tags